Перенесенный рак: что делать с климактерическим синдромом – проблема и решение

1. Deli T., Orosz M., Jakab A. Hormone replacement therapy in cancer survivors - review of the literature. Pathol. Oncol. Res. 2020; 26(1): 63-78. https://dx.doi.org/10.1007/s12253-018-00569-x.
2. Zhu D., Chung H.F., Pandeya N., Dobson A.J., Kuh D., Crawford S.L. et al. Body mass index and age at natural menopause: an international pooled analysis of 11 prospective studies. Eur. J. Epidemiol. 2018; 33(8): 699-710. https://dx.doi.org/10.1007/s10654-018-0367-y.
3. Overbeek A., van den Berg M.H., van Leeuwen F.E., Kaspers G.J., Lambalk C.B., van Dulmen-den Broeder E. Chemotherapy-related late adverse effects on ovarian function in female survivors of childhood and young adult cancer: A systematic review. Cancer Treat. Rev. 2017; 53: 10-24. https://dx.doi.org/10.1016/j.ctrv.2016.11.006
4. Hickey M., Basu P., Sassarini J., Stegmann M.E., Weiderpass E., Nakawala Chilowa K. et al. Managing menopause after cancer. Lancet. 2024; 403(10430): 984-96. https://dx.doi.org/10.1016/S0140-6736(23)02802-7.
5. Saeaib N., Peeyananjarassri K., Liabsuetrakul T., Buhachat R., Myriokefalitaki E. Hormone replacement therapy after surgery for epithelial ovarian cancer. Cochrane Database Syst. Rev. 2020; 1(1): CD012559. https://dx.doi.org/10.1002/14651858.CD012559.pub2.
6. Pergialiotis V., Pitsouni E., Prodromidou A., Frountzas M., Perrea D.N., Vlachos G.D. Hormone therapy for ovarian cancer survivors: systematic review and meta-analysis. Menopause. 2016; 23(3): 335-42. https://dx.doi.org/10.1097/GME.0000000000000508.
7. Li D., Ding C.Y., Qiu L.H. Postoperative hormone replacement therapy for epithelial ovarian cancer patients: a systematic review and meta-analysis. Gynecol. Oncol. 2015; 139(2): 355-62. https://dx.doi.org/10.1016/j.ygyno.2015.07.109.
8. Eeles R.A., Morden J.P., Gore M., Mansi J., Glees J., Wenczl M. et al. Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: results of the AHT randomized trial. J. Clin. Oncol. 2015; 33(35): 4138-44. https://dx.doi.org/10.1200/JCO.2015.60.9719.
9. Brennan A., Brennan D., Rees M., Hickey M. Management of menopausal symptoms and ovarian function preservation in women with gynecological cancer. Int. J. Gynecol. Cancer. 2021; 31(3): 352-9. https://dx.doi.org/10.1136/ijgc-2020-002032.
10. Villa P., Bounous V.E., Amar I.D., Bernardini F., Giorgi M., Attianese D. et al. Hormone replacement therapy in post-menopause hormone-dependent gynecological cancer patients: a narrative review. J. Clin. Med. 2024; 13(5): 1443. https://dx.doi.org/10.3390/jcm13051443.
11. Sinno A.K., Pinkerton J., Febbraro T., Jones N., Khanna N., Temkin S. et al. Hormone therapy (HT) in women with gynecologic cancers and in women at high risk for developing a gynecologic cancer: A Society of Gynecologic Oncology (SGO) clinical practice statement: This practice statement has been endorsed by The North American Menopause Society. Gynecol. Oncol. 2020; 157(2): 303-6. https://dx.doi.org/10.1016/j.ygyno.2020.01.035.
12. Rees M., Angioli R., Coleman R.L., Glasspool R., Plotti F., Simoncini T. et al. European Menopause and Andropause Society (EMAS) and International Gynecologic Cancer Society (IGCS) position statement on managing the menopause after gynecological cancer: focus on menopausal symptoms and osteoporosis. Maturitas. 2020; 134: 56-61. https://dx.doi.org/10.1016/j.maturitas.2020.01.005.
13. Bourdel N., Huchon C., Abdel Wahab C., Azaïs H., Bendifallah S., Bolze P.A. et al. Borderline ovarian tumors: Guidelines from the French national college of obstetricians and gynecologists (CNGOF). Eur. J. Obstet. Gynecol. Reprod. Biol. 2021; 256: 492-501. https://dx.doi.org/10.1016/j.ejogrb.2020.11.045.
14. Gershenson D.M. Clinical management potential tumours of low malignancy. Best Pract. Res. Clin. Obstet. Gynaecol. 2002; 16(4): 513-27. https://dx.doi.org/10.1053/beog.2002.0308.
15. Silverberg S.G., Bell D.A., Kurman R.J., Seidman J.D., Prat J., Ronnett B.M. et al. Borderline ovarian tumors: key points and workshop summary. Hum. Pathol. 2004; 35(8): 910-7. https://dx.doi.org/10.1016/j.humpath.2004.03.003.
16. Seidman J.D., Soslow R.A., Vang R., Berman J.J., Stoler M.H., Sherman M.E. et al. Borderline ovarian tumors: diverse contemporary viewpoints on terminology and diagnostic criteria with illustrative images. Hum. Pathol. 2004; 35(8): 918-33. https://dx.doi.org/10.1016/j.humpath.2004.03.004.
17. Bodner K., Laubichler P., Kimberger O., Czerwenka K., Zeillinger R., Bodner-Adler B. Oestrogen and progesterone receptor expression in patients with adenocarcinoma of the uterine cervix and correlation with various clinicopathological parameters. Anticancer Res. 2010; 30(4): 1341-5.
18. Ploch E. Hormonal replacement therapy in patients after cervical cancer treatment. Gynecol. Oncol. 1987; 26(2): 169-77. https://dx.doi.org/10.1016/0090-8258(87)90270-8.
19. Lacey J.V. Jr., Brinton L.A., Barnes W.A., Gravitt P.E., Greenberg M.D., Hadjimichael O.C. et al. Use of hormone replacement therapy and adenocarcinomas and squamous cell carcinomas of the uterine cervix. Gynecol. Oncol. 2000; 77(1): 149-54. https://dx.doi.org/10.1006/gyno.2000.5731.
20. Richardson A., Watson L., Persic M., Phillips A. Safety of hormone replacement therapy in women with a history of cervical adenocarcinoma. Post. Reprod. Health. 2021; 27(3):167-73. https://dx.doi.org/10.1177/20533691211028518.
21. Lee S.H., Cho Y.J., Cho K.J., Ko M.H., Jung S.Y., Chon S.J. et al. Effect of tibolone on the survival of early stage cervical adenocarcinoma patients. Obstet. Gynecol. Sci. 2018; 61(5): 584-9. https://dx.doi.org/10.5468/ogs.2018.61.5.584.
22. Di Donato V., Palaia I., D'Aniello D., Musacchio L., Santangelo G., Di Mauro F. et al. Does hormone replacement therapy impact the prognosis in endometrial cancer survivors? A systematic review. Oncology. 2020; 98(4): 195-201. https://dx.doi.org/10.1159/000505427.
23. Finch A., Evans G., Narod S.A. BRCA carriers, prophylactic salpingo-oophorectomy and menopause: clinical management considerations and recommendations. Womens Health (Lond.). 2012; 8(5): 543-55. https://dx.doi.org/10.2217/whe.12.41.
24. Poggio F., Del Mastro L., Bruzzone M., Ceppi M., Razeti M.G., Fregatti P. et al. Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis. Breast Cancer Res. Treat. 2022; 191(2): 269-75. https://dx.doi.org/10.1007/s10549-021-06436-9.
25. Edey K.A., Rundle S., Hickey M. Hormone replacement therapy for women previously treated for endometrial cancer. Cochrane Database Syst. Rev. 2018; 5(5): CD008830. https://dx.doi.org/10.1002/14651858.CD008830.pub3.
26. Cibula D., Pötter R., Planchamp F., Åvall-Lundqvist E., Fischerová D., Haie Meder C. et al. The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology guidelines for the management of patients with cervical cancer. Int. J. Gynecol. Cancer 2018; 28: 641-55. https://dx.doi.org/10.1097/IGC.000000000000001216.
27. Yang X., Wang C., He X., Wei J., Wang Y., Li X. et al. Hormone therapy for premature ovarian insufficiency patients with malignant hematologic diseases. Climacteric. 2017; 20(3): 268-73. https://dx.doi.org/10.1080/13697137.2017.1309382.
28. MacKie R.M., Bray C.A. Hormone replacement therapy after surgery for stage 1 or 2 cutaneous melanoma. Br. J. Cancer. 2004; 90(4): 770-2. https://dx.doi.org/10.1038/sj.bjc.6601595.
29. Chan J.A., Meyerhardt J.A., Chan A.T., Giovannucci E.L., Colditz G.A., Fuchs C.S. Hormone replacement therapy and survival after colorectal cancer diagnosis. J. Clin. Oncol. 2006; 24(36): 5680-6. https://dx.doi.org/10.1200/JCO.2006.08.0580.
30. Ji J., Sundquist J., Sundquist K. Use of hormone replacement therapy improves the prognosis in patients with colorectal cancer: A population-based study in Sweden. Int. J. Cancer. 2018; 142(10): 2003-10. https://dx.doi.org/10.1002/ijc.31228.
31. Hassan M.M., Botrus G., Abdel-Wahab R., Wolff R.A., Li D., Tweardy D. et al. Estrogen replacement reduces risk and increases survival times of women with hepatocellular carcinoma. Clin. Gastroenterol. Hepatol. 2017; 15(11): 1791-9. https://dx.doi.org/10.1016/j.cgh.2017.05.036.
32. Brennan A., Rees M. Menopausal hormone therapy in women with benign gynaecological conditions and cancer. Best Pract. Res. Clin. Endocrinol. Metab. 2021; 35(6): 101575. https://dx.doi.org/10.1016/j.beem.2021.101575.
33. Zhang X., Du Y., Tan X., Wang H., Li Y., Zhang Z. et al. The relationship between hormone replacement therapy and risk of kidney cancer in women: a meta-analysis. Cancer Control. 2020; 27(2): 1073274820930194. https://dx.doi.org/10.1177/1073274820930194.
34. Clague J., Reynolds P., Henderson K.D., Sullivan-Halley J., Ma H., Lacey J.V. Jr. et al. Menopausal hormone therapy and lung cancer-specific mortality following diagnosis: the California Teachers Study. PLoS One. 2014; 9(7): e103735. https://dx.doi.org/10.1371/journal.pone.0103735.
35. Katcoff H., Wenzlaff A.S., Schwartz A.G. Survival in women with NSCLC: the role of reproductive history and hormone use. J. Thorac. Oncol. 2014; 9(3): 355-61. https://dx.doi.org/10.1097/JTO.0000000000000077.
36. Ganti A.K., Sahmoun A.E., Panwalkar A.W., Tendulkar K.K., Potti A. Hormone replacement therapy is associated with decreased survival in women with lung cancer. J. Clin. Oncol. 2006; 24(1): 59-63. https://dx.doi.org/10.1200/JCO.2005.02.9827.
37. Chlebowski R.T., Schwartz A.G., Wakelee H., Anderson G.L., Stefanick M.L., Manson J.E. et al.; Women's Health Initiative Investigators. Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet. 2009; 374(9697): 1243-51. https://dx.doi.org/10.1016/S0140-6736(09)61526-9.
38. ESHRE, ASRM, CREWHIRL and IMS Guideline Group on POI; Panay N., Anderson R.A., Bennie A., Cedars M., Davies M., Ee C. et al. Evidence-based guideline: premature ovarian insufficiency. Climacteric. 2024; 27(6): 510-20. https://dx.doi.org/10.1080/13697137.2024.2423213.
39. Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L. et al.; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002; 288(3): 321-33. https://dx.doi.org/10.1001/jama.288.3.321.
40. Ossewaarde M.E., Bots M.L., Verbeek A.L., Peeters P.H., van der Graaf Y., Grobbee D.E. et al. Age at menopause, cause-specific mortality and total life expectancy. Epidemiology. 2005; 16(4): 556-62. https://dx.doi.org/10.1097/01.ede.0000165392.35273.d4.
41. van der Schouw Y.T., van der Graaf Y., Steyerberg E.W., Eijkemans J.C., Banga J.D. Age at menopause as a risk factor for cardiovascular mortality. Lancet. 1996; 347(9003): 714-8. https://dx.doi.org/10.1016/s0140-6736(96)90075-6.
42. de Villiers T.J., Gass M.L., Haines C.J., Hall J.E., Lobo R.A., Pierroz D.D. et al. Global consensus statement on menopausal hormone therapy. Climacteric. 2013; 16(2): 203-4. https://dx.doi.org/10.3109/13697137.2013.771520.
43. Baber R.J., Panay N., Fenton A.; IMS Writing Group. 2016 IMS Recommendations on women's midlife health and menopause hormone therapy. Climacteric. 2016; 19(2): 109-50. https://dx.doi.org/10.3109/13697137.2015.1129166.
44. Табеева Г.И., Сметник А.А., Ермакова Е.И. Принципы применения негормональных средств с целью коррекции климактерических нарушений: до, вместо или вместе с менопаузальной гормональной терапией. Акушерство и гинекология. 2023; 9: 192-8.
45. Хаджиева Н.Х., Алиева А.М., Никитин И.Г. Биологическое и хронологическое старение. Пути замедления старения. Акушерство и гинекология. 2024; 8: 40-6.
46. Mu Y., Kou T., Wei B., Lu X., Liu J., Tian H. et al. Soy products ameliorate obesity-related anthropometric indicators in overweight or obese Asian and non-menopausal women: a meta-analysis of randomized controlled trials. Nutrients. 2019; 11(11): 2790. https://dx.doi.org/10.3390/nu11112790.
47. Setchell K.D.R. The history and basic science development of soy isoflavones. Menopause. 2017; 24(12): 1338-50. https://dx.doi.org/10.1097/GME.0000000000001018.
48. Lephart E.D. Modulation of aromatase by phytoestrogens. Enzyme Res. 2015; 2015: 594656. https://dx.doi.org/10.1155/2015/594656.
49. Cassidy A. Potential risks and benefits of phytoestrogen-rich diets. Int. J. Vitam. Nutr. Res. 2003; 73(2): 120-6. https://dx.doi.org/10.1024/0300-9831.73.2.120.
50. Nachvak S.M., Moradi S., Anjom-Shoae J., Rahmani J., Nasiri M., Maleki V. et al. Soy, soy isoflavones, and protein intake in relation to mortality from all causes, cancers, and cardiovascular diseases: a systematic review and dose-response meta-analysis of prospective cohort studies. J. Acad. Nutr. Diet. 2019; 119(9): 1483-1500.e17. https://dx.doi.org/10.1016/j.jand.2019.04.011.
51. Shu X.O., Zheng Y., Cai H., Gu K., Chen Z., Zheng W. et al. Soy food intake and breast cancer survival. JAMA. 2009; 302(22): 2437-43. https://dx.doi.org/10.1001/jama.2009.1783.

Поступила 16.01.2025

Принята в печать 26.01.2025